Committees and groups

The Better Access Evaluation – Clinical Advisory Group (CAG) has been established to give input, advice and feedback on the evaluation of the Better Access initiative.

The Better Access Evaluation – Stakeholder engagement group (SEG) has been established to consult on the evaluation of the Better Access initiative.

The Co-design Working Group (CWG) formed in November 2023 to support the co-design of an Enhanced Consumer Engagement Process for Health Technology Assessment (HTA). The group worked to improve how we include the views of consumers and patients earlier in the medicines listing process.

The Health Technology Assessment (HTA) Consumer Consultative Committee provides strategic advice and support to us and to the principal HTA committees. Acting as an advisory group, it brings consumer views into HTA processes and relevant matters.

The Australian Government announced the members of the Health Technology Assessment Review Implementation Advisory Group (the IAG) on 20 November 2024. The IAG will help guide critical reforms in response to the findings and recommendations of the HTA Review Report which was released in September.

The HTA Review Reference Committee is responsible for overseeing the Health Technology Assessment (HTA) Policy and Methods Review.

This committee provides advice to the department on issues relating to the Prescribed List.

The Medicare Benefits Schedule (MBS) Review Advisory Committee (MRAC) supports the MBS Continuous Review to ensure the MBS is contemporary, sustainable, evidence based, and supports universal access to high value care for all Australians.

The National Health and Medical Research Strategy Interdepartmental Committee (IDC) supports the development of the National Health and Medical Research Strategy (National Strategy).

This Expert Advisory Panel (EAP) advised on research investments under the Medical Research Future Fund (MRFF) to improve outcomes for people experiencing Post-Acute Sequelae of COVID-19 (PASC). PASC is also known as Long COVID.

The Primary Health Research Plan Expert Advisory Panel (EAP) advised on primary health care research investments under the Medical Research Future Fund (MRFF).

The Stoma Product Assessment Panel assesses applications to add stoma products to the Stoma Appliance Scheme Schedule. The panel of experts meets twice a year to review applications from suppliers, and give their recommendation.

The Targeted Translation Research Accelerator Plan Expert Advisory Panel (EAP) advised on investments under the Medical Research Future Fund (MRFF) for research into diabetes and cardiovascular disease.